The Asia Pacific Oral Antiviral Market should witness market growth of 3.2% CAGR during the forecast period (2023-2029).
The market is expanding due to several causes, including an expanding patient population, an increase in viral disease cases, and rising disease awareness. In addition, the market is expanding due to growing awareness of the need for early disease detection, rising healthcare expenditures in emerging nations, rising government and industry investment, and other factors. The market expansion is anticipated to be fueled by regulatory approvals for special drug designation for treatment and a robust R&D pipeline.
Many people with an uncomplicated case of influenza take over-the-counter medications, rest, and drink lots of water to ease their symptoms. Antiviral medications, available by prescription, can shorten recovery from symptoms. Some can also be used in specific circumstances to lessen the likelihood that those exposed to the influenza virus would become ill. The best results from antiviral medications may be seen in people who begin treatment within 48 hours of the onset of symptoms. Therefore, prompt medical examination is crucial for the early treatment of influenza.
The economic growth of this region is influenced by the development of the healthcare infrastructure, the expansion of government initiatives to boost the uptake of treatments and the regional expansion of significant corporations in Asian nations. The rising prevalence of herpes in developing countries such as China and India is also expected to contribute to development. Since there are numerous regional companies, the market is dispersed, which increases the rate at which oral antiviral medications are used for treating herpes. Asia-Pacific offers lucrative potential for key players operating in the market due to improvements in sector infrastructure, a rise in spending power, and the well-established presence of market players in the region.
The China market dominated the Asia Pacific Oral Antiviral Market by Country in 2022 thereby, achieving a market value of $2,989.9 million by 2029. The Japan market is exhibiting a CAGR of 2.6% during (2023-2029). Additionally, The India market would experience a CAGR of 3.8% during (2023-2029).
Based on Indication, the market is segmented into Human Immunodeficiency Virus (HIV), Hepatitis, Influenza and Others. Based on Drug Class, the market is segmented into Reverse Transcriptase Inhibitors, Protease Inhibitors and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb Company, Gilead Sciences, Inc., Viatris, Inc. (Mylan N.V.), AbbVie, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceutical Industries Ltd., and Amneal Pharmaceuticals, Inc.
The market is expanding due to several causes, including an expanding patient population, an increase in viral disease cases, and rising disease awareness. In addition, the market is expanding due to growing awareness of the need for early disease detection, rising healthcare expenditures in emerging nations, rising government and industry investment, and other factors. The market expansion is anticipated to be fueled by regulatory approvals for special drug designation for treatment and a robust R&D pipeline.
Many people with an uncomplicated case of influenza take over-the-counter medications, rest, and drink lots of water to ease their symptoms. Antiviral medications, available by prescription, can shorten recovery from symptoms. Some can also be used in specific circumstances to lessen the likelihood that those exposed to the influenza virus would become ill. The best results from antiviral medications may be seen in people who begin treatment within 48 hours of the onset of symptoms. Therefore, prompt medical examination is crucial for the early treatment of influenza.
The economic growth of this region is influenced by the development of the healthcare infrastructure, the expansion of government initiatives to boost the uptake of treatments and the regional expansion of significant corporations in Asian nations. The rising prevalence of herpes in developing countries such as China and India is also expected to contribute to development. Since there are numerous regional companies, the market is dispersed, which increases the rate at which oral antiviral medications are used for treating herpes. Asia-Pacific offers lucrative potential for key players operating in the market due to improvements in sector infrastructure, a rise in spending power, and the well-established presence of market players in the region.
The China market dominated the Asia Pacific Oral Antiviral Market by Country in 2022 thereby, achieving a market value of $2,989.9 million by 2029. The Japan market is exhibiting a CAGR of 2.6% during (2023-2029). Additionally, The India market would experience a CAGR of 3.8% during (2023-2029).
Based on Indication, the market is segmented into Human Immunodeficiency Virus (HIV), Hepatitis, Influenza and Others. Based on Drug Class, the market is segmented into Reverse Transcriptase Inhibitors, Protease Inhibitors and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb Company, Gilead Sciences, Inc., Viatris, Inc. (Mylan N.V.), AbbVie, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceutical Industries Ltd., and Amneal Pharmaceuticals, Inc.
Scope of the Study
By Indication
- Human Immunodeficiency Virus (HIV)
- Hepatitis
- Influenza
- Others
By Drug Class
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Others
By Distribution Channel
- Drug Store & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Gilead Sciences, Inc.
- Viatris, Inc. (Mylan N.V.)
- AbbVie, Inc.
- GlaxoSmithKline PLC (GSK)
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Oral Antiviral Market by Indication
Chapter 4. Asia Pacific Oral Antiviral Market by Drug Class
Chapter 5. Asia Pacific Oral Antiviral Market by Distribution Channel
Chapter 6. Asia Pacific Oral Antiviral Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Gilead Sciences, Inc.
- Viatris, Inc. (Mylan N.V.)
- AbbVie, Inc.
- GlaxoSmithKline PLC (GSK)
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
Methodology
LOADING...
